CG ONCOLOGY INC(NASDAQ:CGON) stock News

CGON Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: Benzinga

CG Oncology Stock Signals Bullish Momentum Ahead

21 days ago - By: CG Oncology Inc.

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

2 months ago - By: The Motley Fool

Cg Oncology (CGON) Q2 Loss Widens 93%

2 months ago - By: Benzinga

Beyond The Numbers: 7 Analysts Discuss CG Oncology Stock

21 days ago - By: CG Oncology Inc.

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

23 days ago - By: CG Oncology Inc.

CG Oncology Completes Enrollment in PIVOT-006

23 days ago - By: CG Oncology Inc.

CG Oncology Completes Enrollment in PIVOT-006

a month ago - By: CG Oncology Inc.

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

a month ago - By: CG Oncology Inc.

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

4 months ago - By: Zacks Investment Research - Mentions: SLAB LSTR UAA

Company News for May 14, 2025

2 months ago - By: CG Oncology Inc.

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

2 months ago - By: CG Oncology Inc.

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

2 months ago - By: Zacks Investment Research - Mentions: ABUS

Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates

2 months ago - By: Yahoo Finance

CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial

2 months ago - By: CG Oncology Inc.

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals

2 months ago - By: CG Oncology Inc. - Mentions: ANIP

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals

3 months ago - By: Yahoo Finance - Mentions: LEGN MS

H.C. Wainwright Maintains a Buy on Legend Biotech (LEGN) With a $75 Price Target

3 months ago - By: Yahoo Finance - Mentions: MS OKE

Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating

4 months ago - By: CG Oncology Inc.

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

4 months ago - By: CG Oncology Inc.

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

4 months ago - By: Zacks Investment Research - Mentions: JNJ MRK IBRX

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

4 months ago - By: CG Oncology Inc.

CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

5 months ago - By: Zacks Investment Research - Mentions: ATRA

CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: CG Oncology Inc.

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

5 months ago - By: CG Oncology Inc.

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

5 months ago - By: Zacks Investment Research - Mentions: YMAB

CG ONCOLOGY INC (CGON) Stock News

CGON Latest News, Press Relases and Analysis

CG Oncology Stock Signals Bullish Momentum Ahead

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

Cg Oncology (CGON) Q2 Loss Widens 93%

Beyond The Numbers: 7 Analysts Discuss CG Oncology Stock

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

CG Oncology Completes Enrollment in PIVOT-006

CG Oncology Completes Enrollment in PIVOT-006

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

Company News for May 14, 2025

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates

CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals

H.C. Wainwright Maintains a Buy on Legend Biotech (LEGN) With a $75 Price Target

Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates